Evaluation of adherence to treatment by patients seen in a psychosocial care center in northeastern Brazil by Souza, Thaís Teles et al.
*Correspondence: L.J. Quintans-Júnior. Departamento de Fisiologia, Uni-
versidade Federal de Sergipe, 49.000-100 - São Cristovão - Sergipe – Brazil. 
E-mail: lucindo_jr@yahoo.com.br; lucindo@pq.cnpq.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 47, n. 4, oct./dec., 2011
Evaluation of adherence to treatment by patients seen in a 
psychosocial care center in northeastern Brazil
Thaís Teles Souza1, Wellington Barros Silva2, Alexandre Sherlley Casimiro Onofre1, Jullyana de 
Souza Siqueira Quintans1, Fabiana Botelho de Miranda Onofre1, Lucindo José Quintans-Júnior1,*
1Department of Physiology, Federal University of Sergipe, 2Laboratory of Research and Teaching in Social Pharmacy,  
Federal University of Sergipe
In the treatment of mental disorders, nonadherence to medication, the main cause of psychiatric morbidity, 
is observed in about 50% of the cases and is responsible for numerous losses. This study evaluated 
adherence to drug treatment by patients seen in a Psychosocial Care Center (CAPS) in northeastern 
Brazil. Adherence to treatment was evaluated using the Haynes-Sackett and Morisky-Green-Levine 
tests. All patients registered in the CAPS were included in the study (n= 101). Only 11.88% of the 
patients adhered to drug treatment. The main reasons not to use medication were: oblivion (68.83%), 
feeling unwell after taking the medication (54.22%), not having money to buy the medication (43.83%), 
not finding the medication in the public health service (39.94%) and fear of harm that might be caused 
by the drug (28.90%). Furthermore, 85.1% of the patients did not know their diseases, 88.1% did not 
know their treatment, 86.4% did not feel good when they took their medication, and 88.1% took their 
medication incorrectly. The results revealed that the lack of information about diseases and drugs used, 
the nuisance posed by drug therapy and the low access to medications reduce adherence to treatment 
and, consequently, treatment effectiveness.
Uniterms: Treatment adherence. Drug therapy/adherence to treatment. Mental health. Psychosocial 
Care Center.
No tratamento de desordens mentais, a não-adesão ao tratamento ocorre em cerca de 50% dos casos 
e é responsável por inúmeros prejuízos, além de ser a principal causa de morbidade psiquiátrica. O 
presente estudo objetivou avaliar a adesão ao tratamento medicamentoso de pacientes atendidos em um 
Centro de Atenção Psicossocial (CAPS) no Nordeste do Brasil. A avaliação da adesão ao tratamento foi 
feita através dos testes de Haynes-Sackett e Morisky-Green-Levine. Todos os pacientes cadastrados no 
CAPS foram incluídos no estudo (n = 101). Observou-se que apenas 11,88% dos pacientes aderiram ao 
tratamento medicamentoso. As principais razões para o não uso dos medicamentos foram: esquecimento 
(68,83%), sentir-se mal após a ingestão de medicamentos (54,22%), não ter dinheiro para comprar 
medicamentos (43,83%), não encontrar os medicamentos no serviço público de saúde (39,94%) e medo 
dos danos causados pelos medicamentos (28,90%). Além disso, observou-se que 85,1% dos pacientes 
não conheciam suas doenças, 88,1% não conheciam seus tratamentos, 86,4% não se sentiam bem quando 
usavam medicamentos e 88,1% usavam os medicamentos incorretamente. Os resultados demonstram que 
a falta de informação sobre doenças e medicamentos, os danos decorrentes da terapia medicamentosa e 
o baixo acesso aos medicamentos comprometem a adesão ao tratamento e, consequentemente, a eficácia 
do tratamento.
Unitermos: Adesão ao tratamento. Terapia medicamentosa/adesão ao tratamento. Saúde mental. Centro 
de Atenção Psicossocial.
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INTRODUCTION
Poor adherence to medications prescribed for chron-
ic conditions has been cited as a global problem that may 
lead to increased morbidity and mortality (WHO, 2003; 
NEHI, 2009). It increases the costs within healthcare sys-
tems and contributes to substantial worsening of disease 
control and quality of life because patients who discon-
tinue treatment are more likely to experience progression 
of their disability (Rio et al., 2005). Furthermore, adherent 
patients have a better quality of life and less neuropsycho-
logical impairment (Devonshire et al., 2011).
The World Health Organization (WHO) estimates 
an average rate of only 50% adherence for patients with 
chronic medical conditions (WHO, 2003), and some stud-
ies showed that more than 25% of all prescribed doses 
are not taken by patients (DiMatteo, 2004; Gimenes et 
al., 2010). Poor adherence has also been implicated in 
unnecessary and costly procedures and hospitalizations 
(De Oliveira et al., 2004).
Costs estimates of nonadherence in the US revealed 
an investment of more than $100 billion per year, with 
$30 billion in direct medical costs and $70 billion in lost 
productivity, wages, and other economic losses (Sterz et 
al., 2006).
The concept of adherence varies widely in the litera-
ture, but the term can be defined as the use of prescription 
drugs or other procedures at least 80% of the total observ-
ing time, dose and treatment time (Leite, Vasconcellos, 
2003). Adherence to treatment refers to the extent to which 
patients accept and follow the recommendations made by 
physicians or other health professionals regarding the use 
of a particular therapy (Cramer et al., 2008; Rosa et al., 
2006; Dewulf et al., 2006; Santin, Cereser, Rosa, 2005).
The WHO defined adherence as “the extent to which 
a person’s behavior – taking medication, following a diet, 
and/or executing lifestyle changes - corresponds with 
agreed recommendations from a healthcare provider” 
(WHO, 2003).
Several models suggest that the primary factors in ad-
herence to treatment are: state of illness, treatment regimen, 
patient’s relationship with health professionals, poor access 
to medications in the public service and high costs of medi-
cines (Russel, 2010; Cánovas, Hernández, Esteban, 2001).
Nonadherence to treatment by patients with mental 
disorders, the main cause of psychiatric morbidity and 
rehospitalization, is observed in about 50% of cases and is 
responsible for numerous losses. More than 85% of these 
patients suffer the consequences of their behavior at some 
time in the course of their disease (Gray, Wykes, Gournay, 
2002; O’Connor, 2006).
This study evaluated, in an unprecedented way in 
the state of Sergipe, the adherence to drug treatment by 
patients seen in a Psychosocial Care Center (CAPS) in 
northeastern Brazil.
MATERIAL AND METHODS
This study was conducted between August 2009 
and May 2010 at the Psychosocial Care Center (CAPS) 
Valter Correia in the city of Sao Cristovao, Brazil. CAPS, 
a community-based mental health service in Brazil, aims 
to promote the psychosocial rehabilitation of patients.
Adherence to treatment was evaluated during inter-
views with patients (and/or their caregivers) by assessing 
the knowledge of patients (and/or their caregivers) about 
their medications and diseases and applying the Haynes 
Sackett and Morisky-Green-Levine tests. In addition, we 
evaluated the possible causes for nonadherence to treat-
ment. 
All patients registered in the CAPS (or their caregiv-
ers) were included in the study (n=101). The study was 
approved by the Ethics Committee of Federal University 
of Sergipe. The results were organized and analyzed sta-
tistically using the EPI-INFO 3.5.1 software.
We evaluated statistically significant differences 
(p <0.05) in the correlations between adherence to drug 
treatment and the study parameters. Table I shows the 
parameters and their variables correlated with adherence 
to treatment.
RESULTS
During the study, CAPS Valter Correia had 101 
patients. Most were men (58.4%), illiterate (51.5%) and 
without any monthly income (49.5%). The average age 
of patients was 42.2 years (SD = 12.0), and schizophrenia 
was the most frequent mental disorder (31.5%). The aver-
age number of medications by patient was 3.11 (SD=1.41), 
and the older group of patients (75-80 years) had the 
largest consumption of medications (5.50 drugs/patient).
The Haynes-Sackett and Morisky-Green-Levine 
tests revealed that only 11.88% of the patients adhered 
to drug treatment. The main reasons reported by patients 
(and/or their caregivers) for not using medications are 
shown in Figure 1.
Table II describes the behavior of patients seen at 
CAPS regarding their illnesses, health problems and drug 
use.
Table III shows the main types of discomfort re-
ported by patients (and/or their caregivers) during the use 
of medications.
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TABLE I - Parameters and variables correlated with adherence to treatment of patients seen at a Psychosocial Care Center (CAPS) 
in northeastern Brazil (August 2009 to May 2010)
Parameters Variables
Sex Female and Male
Regime Intensive, Semi-intensive and Non-intensive
Age group 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74 and 
75-80 years
Income No income, 1 minimum wage, 2 minimum wages and 3 minimum wages
Education Illiterate, incomplete primary school, primary school, incomplete secondary school 
and secondary school
Benefit/pensions Recipient and Non-recipient
Marital status Single, Married, Divorced and Widowed
Number of disorders 1, 2, 3 and 4
Number of mental disorders 1, 2 and 3
Number of associated diseases 0, 1, 2 and 3
Number of medications 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
Number of psychotropic medications 0, 1, 2, 3, 4, 5 and 6
Number of non-psychotropic medications 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Nuisance posed by the use of medications Much, Little and No
Knowledge about the disease Yes and No
Knowledge about medications Yes and No
Help received with treatment Yes and No
Use of medications Correct and Incorrect
Drug interactions Yes and No
Difficulty in taking medications Yes and No
Alcohol consumption < 2 cups/week, > 6 cups/week, 2-6 cups/week, occasionally, did not consume and 
trying to stop
Smoking < 1 pack/day, > 1 pack/day, did not smoke
Coffee consumption < 2 cup/day, > 6 cups/day, 2-6 cups/day, occasionally, history of dependence, did 
not consume and trying to stop
Illicit drug consumption > 6 times/week, 2-6 times/week, occasionally, history of dependence and did not 
consume
Consumption of tea < 2 cups/day, > 2 cups/day, occasionally, did not consume
We observed statistically significant differences 
(p <0.05) in the correlations between adherence to drug 
treatment and some parameters of this study, as shown in 
Table IV.
DISCUSSION
Mental disorders are socially relevant health prob-
lems because of their high incidence in populations of 
different countries and culturally distinct societies. It 
is estimated that the prevalence of mental disorders in 
the Brazilian population varies from 20% to 56%, af-
fecting mainly women and workers (Santos, Siqueira, 
2010).
The Brazilian Mental Health Policy is essentially 
based on the Caracas Declaration (PAHO/WHO, 1991; 
Ministry of Health, 2005). Its four main points are de-
scribed as follows: a) to guarantee civil rights for people 
with mental disorders according to the Principles for 
the Protection of Persons With Mental Illness and the 
Improvement of Mental Health Care; b) to decentralize 
psychiatric care; c) to protect patients under treatment 
in the existing hospitals; and d) to develop a diverse net-
work to provide access and efficiency for those patients. 
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FIGURE 1 - Main reasons for not using medications reported by patients (and/or their caregivers) at a Psychosocial Care Center 
(CAPS) in northeastern Brazil (August 2009 to May 2010).
TABLE II - Behavior of patients seen at a Psychosocial Care 
Center (CAPS) in northeastern Brazil regarding their illnesses, 
health problems and drug use (August 2009 to May 2010) 
Parameters Variable %
Do you know your 
disease(s)?
No 85.15 
Yes 14.85 
Do you know your 
treatment?
No 88.17
Yes 11.83
Did you receive help with 
treatment?
Yes 32.67
No 67.33 
Do you use the medication? Sometimes 20.45
No 25.97
Yes 53.57
Do you use the medication 
properly?
No 88.12
Yes 11.88
What is the dose used? Below prescribed 40.91
Above prescribed 14.94
Prescribed 44.16
How did it feel when you 
used it?
Not well 86.36
Well 11.04
Great 2.60
Do you feel any discomfort? A lot 69.16
A little 20.45
No 10.39
TABLE III - Main types of discomfort during the use of 
medications reported by patients (and/or their caregivers) at 
a Psychosocial Care Center (CAPS) in northeastern Brazil 
(August 2009 to May 2010)
Discomfort Relative frequency (%) 
Anxiety 63.37
Dry mouth 45.54
Difficulty concentrating 88.12
Decreased libido 23.76
Headache 68.32
Stomachache 57.43
Lack of appetite 30.69
Weight change 26.73
Nausea 70.30
Paresthesias 22.77
Memory loss 35.64
Drowsiness 84.16
Tremor 50.50
Dizziness 75.25
The Brazilian Ministry of Health supported the project 
for a Mental Health Law, which essentially proposes the 
progressive replacement of psychiatric beds with Com-
munity Social Psychiatric Centers, called Psychosocial 
Care Centers (CAPS) (Ministry of Health, 2004).
CAPS have become the cornerstone of the Brazil-
ian Psychiatric Reform. These community services are 
responsible for treating severe mental disorders and ar-
ticulating the liaison with primary care units to coordinate 
psychiatric care in a defined catchment area. The matrix 
of mental health care should be centralized at the CAPS 
level, where many actions should take place, such as su-
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TABLE IV - Correlation with statistically significant differences (p <0.05) between the study parameters and adherence to treatment 
of patients seen at a Psychosocial Care Center (CAPS) in northeastern Brazil (August 2009 to May 2010)
Parameters Correlation with adherence to treatment
Regime 100% of intensive, 0% of semi-intensive and 0% of non-intensive patients adhered to treatment. Among 
patients who adhered, 100% were taking the intensive regime.
Income 20.4% of those who earned one, 100% of those who earned two, 100% of those who earned three minimum 
wages and 0% of those without income adhered to treatment. Among patients who adhered, 83.3% earned 
one, 8.3% earned two and 8.3% earned three minimum wages.
Education 0% of illiterate patients, 0% of those with an incomplete primary education, 0% of those with a complete 
primary education, 100% of those with an incomplete secondary education and 100% of those with 
a complete secondary education adhered to treatment. Among patients who adhered, 33.3% had an 
incomplete secondary education and 66.7% had a complete secondary education.
Benefits/pension 0% of those who received no benefit and 23.5% of those who received benefits adhered to treatment. 
Among patients who adhered, 100% received benefits.
Marital status 70.6% of married, 0% of divorced, 0% of unmarried and 0% of widowed patients adhered to treatment. 
Among patients who adhered to treatment, 100% were married.
Number of 
medications 
100% of those who did not use drugs, 100% of those who used 1 drug, 11.1% of those who used 2 drugs 
and 0% of those who used more than 3 drugs adhered to treatment. Among patients who adhered, 8.3% 
did not use drugs, 66.7% used 1 drug and 25% used 2 drugs.
Number of 
psychotropic 
medications
100% of those who did not use drugs, 80% of those who used 1 drug, 8.8% of those who used 2 drugs and 
0% of those who used more than 3 drugs adhered to treatment. Among patients who adhered to treatment, 
8.3% did not use drugs, 66.7% used 1 drug and 25% used 2 drugs.
Nuisance posed by 
the use of drugs
0% of those who experienced a lot of nuisance, 0% of those who experienced a little nuisance and 
100% of those without any nuisance adhered to treatment. Among patients who adhered, 100% did not 
experience any nuisance.
Knowledge about 
the disease 
62.5% of those who knew the disease and 2.4% of those who did not know it adhered to treatment. Among 
patients who adhered, 83.3% knew the disease and 16.7% did not know it.
Knowledge about 
medications 
100% of those who knew the medication and 0% of those who did not know the medication adhered to 
treatment. Among patients who adhered, 100% knew the medication.
Received help with 
treatment 
27.3% of those who received help and 4.4% of those who did not receive any help adhered to treatment. 
Among patients who adhered, 75% received help and 25% did not receive any help.
Use of medications 91.7% of those who used the medications correctly and 1.1% of those used it incorrectly adhered to 
treatment. Among patients who adhered, 91.7% used it correctly and 8.3% used it incorrectly.
Difficulty in taking 
medication
100% of those who had no difficulty and 0% of those who had difficulty in taking medication adhered to 
treatment. Among patients who adhered, 100% had no difficulty in taking medication.
Alcohol consumption 15.8% of those who did not consume, 0% of those who consumed < 2 cups/week, 0% of those who 
consumed > 6 cups/week, 0% of those who consumed 2-6 cups/week, 0% of those who consumed it 
occasionally and 0% of those who were trying to stop drinking adhered to treatment. Among patients 
who adhered, 100% did not consume alcohol.
Smoking 19% of those who did not smoke, 0% of those who smoked < 1 pack/day and 0% of those who smoked 
> 1 pack/day adhered to treatment. Among patients who adhered, 100% did not smoke.
Consumption of tea 33.3% of those who did not consume tea, 0% of those who consumed < 2 cups/day, 0% of those who 
consumed > 2 cups/day and 0% of those who consumed it occasionally adhered to treatment. Among 
patients who adhered, 100% did not consume tea.
pervision and brief training of mental health workers and 
the involvement of families and patients to combat stigma. 
CAPS should also be the main center of referral for severe 
cases, averting in-ward admissions (psychiatric hospitals 
or psychiatric wards in general hospitals) whenever pos-
sible. The purpose of CAPS is both to provide for the vari-
ous needs of patients with serious mental disorders and to 
act in coordination with the primary care services to treat 
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those mental disorders that are most prevalent among the 
population (Mateus et al., 2008).
Poor adherence to medication is growing and is 
recognized as a significant source of waste in the Brazilian 
health care system. Poor adherence often leads to prevent-
able worsening of the disease, posing serious and unnec-
essary health risks, particularly for patients with chronic 
illnesses. Nonadherence to medication, found in about 
50% of all cases, is responsible for numerous losses and 
the main cause of psychiatric morbidity and readmissions 
(O’Connor, 2006; Osterberg, Blaschke, 2005).
In addition, nonadherence alone has been shown to 
result in $100 billion in excess hospitalizations each year. 
The NEHI estimates that nonadherence, together with 
suboptimal prescribing, drug administration and diagnosis, 
may result in as much as $290 billion in avoidable medical 
spending per year, or 13 percent of the total health care 
expenditures (NEHI, 2009).
Our study found that only 11.88% of all patients 
adhered to drug treatment. The main reasons reported by 
patients (and/or their caregivers) for not using medica-
tions (Figure 1) were oblivion, feeling unwell after tak-
ing medications, low access to medications, difficulty 
swallowing, fear of harm that might be caused by drug 
and fear of dependence/addiction. These results are in 
agreement with findings reported in another study, which 
claimed that nonadherence to drug treatment for patients 
with mental disorders is determined by different factors 
(Kurita, Pimenta, 2004). In general, more expensive, time 
consuming, disruptive or complex treatment regimens 
lower the odds of adherence by the patient and interfere 
with the disease and, consequently, the patient’s quality 
of life, which decreases the safety and effectiveness of 
pharmacotherapy (OPAS, OMS, 2001; Freitas, Maia, 
Iodes, 2006).
Only a minority of people with mental disorders 
worldwide consult a physician (Andrews et al., 2000; 
Kapczinski et al., 2001). Although there is evidence from 
industrialized countries that not all people with mental 
disorders receive adequate treatment, health systems in 
developing countries are often not able to provide even the 
most essential mental health care (Andrews et al., 2000).
Emotional and cognitive issues may also be im-
portant; patients with decreased memory function, or 
increased levels of anxiety or fatigue, have lower levels of 
adherence; patients with a current mood or anxiety disor-
der were almost five times more likely to be nonadherent 
(Bruce et al., 2010).
Furthermore, we observed (Table II) that 85.15% of 
the patients did not know their diseases, 88.17% did not 
know their treatments, 67.33% did not receive help with 
the treatment, 86.36% did not feel good when using their 
medications and 88.12% used the medications incorrectly. 
These results suggest that the lack of information com-
promises adherence and treatment effectiveness (Cipolle, 
Strand, Morley, 2000), whereas the active participation of 
the user and/or caregiver and their responsibility for the 
treatment are vital to the success of drug therapy (Rathod 
et al., 2008; Miklowitz et al., 2003).
The main types of discomfort reported by patients 
(and/or their caregivers) during the use of medications 
(Table III) were: difficulty concentrating, drowsiness, 
dizziness, nausea, headache, anxiety, stomachache, tremor 
and dry mouth. These results were similar to those reported 
in other studies, which demonstrated the relationship be-
tween the process of using drugs and the morbidity and 
mortality associated with drugs that may trigger adverse 
reactions. In those studies, problems such as adverse reac-
tions, noncompliance, overdose and inadequate therapy 
lead to treatment failure, and, if not detected and resolved, 
may lead to death (Hafner et al., 2002; Lara, Abreu, 2000; 
Hepler, Strand, 1999; Spina et al., 2008).
The behavior of nonadherence is a complex and 
universal phenomenon. In the course of psychiatric treat-
ment, noncompliance develops gradually and is related to 
disease aggravation (Davis, Chen, 2003; Bechelli, 2003).
We observed statistically significant differences (p 
<0.05) in the correlations between adherence to drug treat-
ment and the following parameters (Table IV): regime, 
income, education, benefit/pension, marital status, number 
of medications, number of medications prescribed by the 
CAPS doctor, nuisance posed by the use of medications, 
knowledge about the disease, knowledge about medica-
tions, help received with treatment, use of medications, 
difficulty in taking medications, alcohol consumption, 
smoking and consumption of tea. These results are sup-
ported by key factors that affect patient adherence accord-
ing to the WHO (2003). Briefly, they are:
•	 Social and Economic Factors, including socioeco-
nomic status, degree of literacy/education, employment/
non-employment, social support networks, distance from 
treatment centers, cost of transportation, cost of medica-
tion, culture and beliefs about illness and treatment and 
family function/dysfunction, which are some of the key 
elements falling within this category.
•	 Healthcare Team and System-Related Factors, 
including the provider-patient relationship. Poorly de-
veloped health services with inadequate reimbursement, 
poor medication distribution systems, lack of knowledge/
training about managing chronic disease for healthcare 
providers, all impact adherence negatively.
•	 Condition Related Factors reflect various illness-
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related factors faced by the patient, including severity of 
symptoms, level of disability, comorbidities, and physical 
and psychological effects of the illness.
•	 Therapy Related Factors, including complexity of 
the medication regime, duration of treatment, side effects, 
previous treatment successes/failures, and immediacy and 
visibility of beneficial effects.
•	 Patient Related Factors, covering such areas as 
patient’s knowledge and beliefs about their illness, per-
ceptions of personal need for the medication/treatment, 
anxieties/stress about possible side effects, expectations 
regarding the outcome of treatment and the patient’s cost/
benefit analysis of adhering to the regimen.
To be truly successful, an adherence program must 
operate on all these levels identified by the WHO, and be a 
cooperative effort between the patient, healthcare provid-
ers, Government and industry.
CONCLUSION
The results of this study revealed that nonadherence 
to treatment by patients with mental disorders is a serious 
and persistent problem correlated with lack of information 
about diseases and drugs used, nuisance posed by drug 
therapy, low access to medications, poor monitoring by 
health service, poor education, large number of medica-
tions used, alcohol consumption, smoking and consump-
tion of tea.
Cost-effective strategies to promote adherence, 
maximize the benefits and minimize the risks to patients 
should be identified and associated with the different fac-
tors that affect patient adherence.
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